Please login to the form below

Not currently logged in
Email:
Password:

Isentress

This page shows the latest Isentress news and features for those working in and with pharma, biotech and healthcare.

A new option for people with HIV

A new option for people with HIV

Other integrase inhibitors. Raltegravir ( Isentress; Merck) was the first integrase inhibitor to be approved by the US FDA in October 2007. ... tenofovir disoproxil fumarate (Atripla) and raltegravir (Isentress).

Latest news

  • FDA clears Isentress formulation for infants with HIV FDA clears Isentress formulation for infants with HIV

    FDA clears Isentress formulation for infants with HIV. Merck's integrase inhibitor available for children as young as four weeks. ... By expanding the potential audience of Isentress, Merck will hope it can keep up in an increasingly competitive market

  • ViiV's Tivicay for HIV on course for EU approval ViiV's Tivicay for HIV on course for EU approval

    Tivicay is the third entrant in the integrase inhibitor class after Merck &Co's Isentress (raltegravir) - which was first approved in 2007 - and Gilead Sciences' elvitegravir which was approved last year ... As the first entrant, Isentress is enjoying

  • ViiV gets US nod for HIV drug dolutegravir ViiV gets US nod for HIV drug dolutegravir

    a twice-daily treatment with rival integrase inhibitor Isentress (raltegravir) from Merck &Co and found they were equivalent in previously-untreated HIV patients. ... The SAILING study found that Tivicay was more effective than Isentress in suppressing

  • Merck profit slides as generics continue to bite Merck profit slides as generics continue to bite

    HIV drug Isentress (raltegravir) climbed 5 per cent to $410m, holding up fairly well despite increased competition from the likes of Gilead Sciences' elvitegravir, while sales of cholesterol drugs Zetia (ezetimibe)

  • GSK boost vaccines capabilities with €250m Okairos purchase GSK boost vaccines capabilities with €250m Okairos purchase

    It was founded by the same team who founded Istituto di Ricerche di Biologia Molecolare (IRBM) – the company that discovered HIV treatment Isentress (raltegravir) before becoming a subsidiary of Merck.

More from news
Approximately 1 fully matching, plus 29 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics